• Atossa Therapeutics flagged peer-reviewed publication of results from KARISMA Endoxifen trial in Journal of National Cancer Institute, with results already presented via publication.
• Phase 2 study in healthy premenopausal women showed low-dose oral endoxifen reduced mammographic breast density versus placebo, supporting its positioning as potential breast cancer risk-reduction option.
• Lower dose delivered meaningful effect with tolerability broadly similar to placebo, while higher dose drove more treatment-related discontinuations, shaping dose selection for future development.
• Program rationale centers on bypassing tamoxifen metabolism variability by dosing active metabolite directly, aiming to improve predictability and long-term acceptability in prevention setting.
• Next step remains clinical work to determine whether endoxifen lowers breast cancer incidence in higher-risk women, beyond biomarker changes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605060830PR_NEWS_USPR_____SF52109) on May 06, 2026, and is solely responsible for the information contained therein.